Darryl McDougald

Darryl McDougald has a strong background in scientific research and nuclear chemistry. Darryl has held various roles throughout their career. From 2022 to present, they have been a Principal Scientist at Solve Therapeutics, Inc. Before that, from 2017 to 2022, they worked as a Nuclear Chemist at Cereius Inc. Prior to that, they worked at Duke University Medical Center from 2008 to 2022 as a Principle Investigator, focusing on nuclear medicine targets for use in Positron Emission Tomography (PET). Darryl also has experience at GSK, where they worked as a Research Scientist and Principle Scientist from 1998 to 2008.

Darryl McDougald holds a Bachelor of Science (BS) degree in Chemistry from the University of North Carolina Wilmington. Darryl also has a Master's degree from the University of North Carolina at Chapel Hill, although the specific field of study for their master's degree is unknown.